Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Antonio Ribeiro-Oliveira$suffix/text()$suffix/text(), Richard A. Brook, Kathryn A. Munoz, Ian A. Beren, John D. Whalen, Nathan L. Kleinman & Kevin C. J. Yuen. (2021) Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care. Journal of Medical Economics 24:1, pages 432-439.
Read now
Read now
Nakhleh E Abu-Yaghi, Alaa M Abed, Dana F Khlaifat, Mohammed B Nawaiseh, Laith O Emoush, Heba Z AlHajjaj, Ala M Abojaradeh, Mariana N Hattar, Sura K Abusaleem, Hashem M Sabbagh, Yazan A Abu Gharbieh & Sura A Quaqazeh. (2020) Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients. Clinical Ophthalmology 14, pages 921-929.
Read now
Read now
Dimitrios A Karagiannis, Meropi Lygerou, Georgios Papadopoulos, Stamatina A Kabanarou, Miltiadis Aspiotis, Doukas C Dardabounis, Panagiotis G Minakakis, Sofia I Spai, Chrysanthi Koutsandrea, Panagiotis Oikonomidis, Georgia N Pantelopoulou, Olga C Kousidou & Miltiadis Tsilimbaris. (2020) A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study. Clinical Ophthalmology 14, pages 1417-1426.
Read now
Read now
Szilárd Kiss, Hitesh S Chandwani, Ashley L Cole, Vaishali D Patel, Orsolya E Lunacsek & Pravin U Dugel. (2016) Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clinical Ophthalmology 10, pages 2443-2453.
Read now
Read now
Articles from other publishers (13)
Karen Mulligan, Jaehong Kim, Bryan Tysinger, Jill Blim, Geoffrey Emerson, Philip J. Ferrone, Judy E. Kim, Seth Seabury & Paul Hahn. (2023) The Broader Economic Value of Treatment for Diabetic Macular Edema. Diabetes Care 46:6, pages 1196-1203.
Crossref
Crossref
Ana Patricia Marques, Jacqueline Ramke, John Cairns, Thomas Butt, Justine H. Zhang, Iain Jones, Marty Jovic, Allyala Nandakumar, Hannah Faal, Hugh Taylor, Andrew Bastawrous, Tasanee Braithwaite, Serge Resnikoff, Peng T. Khaw, Rupert Bourne, Iris Gordon, Kevin Frick & Matthew J. Burton. (2022) The economics of vision impairment and its leading causes: A systematic review. eClinicalMedicine 46, pages 101354.
Crossref
Crossref
Matias Iglicki, David Pérez González, Anat Loewenstein & Dinah Zur. (2021) Next-generation anti-VEGF agents for diabetic macular oedema. Eye 36:2, pages 273-277.
Crossref
Crossref
Richard A Brook, Nathan L Kleinman & Ian A Beren. (2021) Rheumatoid Arthritis Disability and Absence Trends in the United States. Journal of Biomedical Research & Environmental Sciences 2:12, pages 1238-1245.
Crossref
Crossref
Richard A. Brook, Nathan L. Kleinman & Ian A. Beren. (2021) Disability and workers' compensation trends for employees with mental disorders and SUDs in the United States. Mental Health Clinician 11:5, pages 279-286.
Crossref
Crossref
Arshad M. Khanani, Sunil S. Patel, Victor H. Gonzalez, Suk J. Moon, Glenn J. Jaffe, John A. Wells, Petra Kozma, Pravin U. Dugel & Raj K. Maturi. (2021) Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema. Ophthalmology Science 1:3, pages 100040.
Crossref
Crossref
O. A. E. Cooper, D. J. Taylor, D. P. Crabb, D. A. Sim & H. McBain. (2019) Psychological, social and everyday visual impact of diabetic macular oedema and diabetic retinopathy: a systematic review. Diabetic Medicine 37:6, pages 924-933.
Crossref
Crossref
Abdulkarim M. Meraya, Monira Alwhaibi, Moteb A. Khobrani, Hafiz A. Makeen, Saad S. Alqahtani & David Banji. (2020) Direct Medical Expenditures Associated with Eye Complications among Adults with Diabetes in the United States. Journal of Diabetes Research 2020, pages 1-12.
Crossref
Crossref
Amanda J. Lu, Allison J. Chen, Vicky Hwang, Pui Yee Law, Jay M. Stewart & Daniel L. Chao. (2019) Analysis of Patient-Reported Barriers to Diabetic Retinopathy Follow-Up. Ophthalmic Surgery, Lasers and Imaging Retina 50:2, pages 99-105.
Crossref
Crossref
Matias Iglicki, Alejandro Lavaque, Malgorzata Ozimek, Hermino Pablo Negri, Mali Okada, Jay Chhablani, Catharina Busch, Anat Loewenstein & Dinah Zur. (2018) Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: The VITAL Study. PLOS ONE 13:7, pages e0200365.
Crossref
Crossref
Jeremy D. Gale, Brian Berger, Steven Gilbert, Serghei Popa, Marla B. Sultan, Ronald A. Schachar, Douglas Girgenti & Christelle Perros-Huguet. (2018) A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Investigative Opthalmology & Visual Science 59:6, pages 2659.
Crossref
Crossref
M.J. Abraldes, A. Pareja & M. Roura. (2016) Analysis of costs associated with the management and morbidity of diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Archivos de la Sociedad Española de Oftalmología (English Edition) 91:6, pages 273-280.
Crossref
Crossref
M.J. Abraldes, A. Pareja & M. Roura. (2016) Análisis de los costes asociados al manejo y morbilidad del edema macular diabético y el edema macular secundario a oclusión venosa de la retina. Archivos de la Sociedad Española de Oftalmología 91:6, pages 273-280.
Crossref
Crossref